The latest move by the Centre is significant as this is for the first time that a booster dose that is different from the one used for primary vaccination against Covid-19 has been allowed in the country.
India has so far reported eight cases of monkeypox, of which five have been from Kerala and three from Delhi. Of the five patients in Kerala, one succumbed to the disease on July 30, making it India's first monkeypox fatality.
SII manufactures Covovax under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid and has been dispatched to New Zealand, Netherlands, Australia and Indonesia, where a total of at least 100 million doses have been sent.